Summary & Overview
CPT 81430: Genomic Sequence Analysis Panel for Hearing Loss and Related Genes
CPT code 81430 represents a genomic sequence analysis panel designed to evaluate a patient specimen for genetic sequences across at least 60 genes, including 16 genes associated with hearing loss. This code is significant nationally as it supports advanced molecular diagnostics, enabling clinicians to identify genetic factors that may contribute to hearing impairment and other conditions. The procedure is typically performed in laboratory settings and is part of the broader category of Genomic Sequencing Procedures and Other Molecular Multianalyte Assays.
Major payers covering this code include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication provides an overview of payer coverage, clinical context, and policy updates relevant to this code. Readers will gain insights into benchmarks for utilization, recent changes in payer policies, and the clinical applications of genomic sequencing panels. The summary also highlights the importance of this code in expanding access to precision medicine and supporting evidence-based care for patients with suspected genetic hearing loss and other related conditions.
Key topics include payer coverage trends, clinical indications, and the role of laboratories in delivering these advanced diagnostic services. The publication is intended for healthcare professionals, policy analysts, and laboratory administrators seeking up-to-date information on CPT code 81430 and its impact on clinical practice and reimbursement.
CPT Code Overview
CPT code 81430 is used for genomic sequence analysis panels that evaluate a patient specimen for genetic sequences of at least 60 genes. This includes 16 specific genes listed in the code descriptor, which may relate to hearing loss. The procedure falls under Genomic Sequencing Procedures and Other Molecular Multianalyte Assays, providing comprehensive genetic information that can inform clinical decision-making, particularly in cases involving hearing impairment. The typical site of service for this procedure is a laboratory (POS 81), where specialized equipment and expertise are required to perform the sequencing and analysis.
Clinical & Coding Specifications
Clinical Context
A patient, often a child or adult presenting with unexplained hearing loss, is referred for genomic sequence analysis to evaluate for potential genetic causes. The ordering provider, such as an audiologist or hearing instrument specialist, collects a specimen (typically blood or saliva) and sends it to a laboratory (Place of Service 81). The laboratory performs a genomic sequencing panel that analyzes at least 60 genes, including 16 specifically associated with hearing loss. The results help guide further clinical management, genetic counseling, and potential treatment options.
Coding Specifications
-
Modifier
26: Used when reporting only the professional component of the service, such as interpretation of the genomic sequencing results by a qualified provider. -
Modifier
TC: Used when reporting only the technical component, which includes specimen processing and laboratory analysis.
| Modifier Code | Description |
|---|---|
26 | Professional Component |